GBG FORSCHUNGS GMBH

Their core work

GBG Forschungs GmbH is the research subsidiary of the German Breast Group (GBG), one of Europe's most active breast cancer clinical trial networks. They bring real patient cohorts, validated clinical protocols, and deep oncology expertise to EU research consortia — capabilities that pure academic institutions cannot replicate. In ONCOBIOME, they contributed clinical cancer data for microbiome-based biomarker discovery across breast, colon, melanoma, and lung cancers; in BIGPICTURE, they are part of building Europe's central digital pathology repository powered by AI. Their value to any consortium is the bridge they provide between laboratory science and clinical reality.

What they specialise in

How they've shifted over time

GBG's first H2020 project (ONCOBIOME, 2019) was rooted in biology and clinical science — gut microbiome profiling, molecular fingerprints, cancer biomarkers, and precision medicine across multiple tumor types. Their second project (BIGPICTURE, 2021) marked a clear shift toward digital infrastructure and artificial intelligence, with keywords narrowing entirely to AI and digital pathology. In just two projects, GBG traces the broader oncology field's trajectory: from wet-lab biomarker discovery toward AI-enabled computational diagnostics, suggesting they are deliberately repositioning as a clinical data node for digital oncology platforms.

GBG is moving from biological research participation toward digital pathology and AI diagnostics, likely leveraging their clinical cohort access as the asset that makes them attractive to data-hungry computational oncology projects.

How they like to work

GBG participates exclusively as a consortium partner — never as coordinator — across both projects, indicating they operate as a specialist contributor rather than a project driver. Despite this supporting role, they are embedded in very large consortia: 71 unique partners from just 2 projects points to pan-European networks of 30+ organizations each. This suggests they are sought-after as a clinical node that gives large research consortia access to real-world oncology data and trial infrastructure.

GBG has connected with 71 unique partners across 16 countries through only 2 projects, indicating deep embeddedness in large, internationally distributed oncology consortia. Their network spans a substantial portion of the EU research landscape for cancer biology and digital health infrastructure.

What sets them apart

What sets GBG Forschungs GmbH apart is their direct connection to one of Germany's leading breast cancer clinical trial networks — they are not a generic biotech SME but the research arm of an organization that runs real patient studies. This gives any consortium access to clinical cohorts, regulatory-grade trial infrastructure, and oncology domain credibility that academic labs cannot easily substitute. For projects needing a partner who can validate findings in actual patients — not just in silico or in vitro — GBG is a rare and valuable node.

Highlights from their portfolio

• ONCOBIOME
  Their largest project by far (€619,312), linking gut microbiome signatures to cancer prognosis across four tumor types — a high-impact, multi-cancer biomarker study running 2019-2025.
• BIGPICTURE
  Participation in building Europe's central digital pathology repository with AI integration signals GBG's strategic move into computational oncology infrastructure at EU scale.